Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05704725 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
A Phase 3 study of Chorioretinal Vascular Disease, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT05704725: Completed Phase 3 study of Chorioretinal Vascular Disease, sponsored by Amgen.
NCT05704725 is a Phase 3 study of Chorioretinal Vascular Disease that has completed, run by Amgen. The registered enrollment target is 49 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05704725, a Phase 3 study of Chorioretinal Vascular Disease, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.
Primary Outcome
A successful injection was defined by whether the retinal specialist administering the IVT injection answered 'yes' to the following question: Did the PFS allow for the safe and effective administration of the prescribed dose? Percentage of successful injections and Clopper-Pearson 95% Confidence Interval is reported.
Conditions Studied
Interventions
- DRUG Aflibercept
- DRUG ABP 938
Study Locations (4)
Texas
- Retina Consultants of Texas - Austin Retina - Austin
- Retina Consultants of Texas - Bellaire Retina Center - Bellaire
- Retinal Consultants of Texas - San Antonio Retina Center - San Antonio
- Retina Consultants of Texas - The Woodlands Retina Center - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2023-03-24 |
| Phase | Phase 3 |
What the finished NCT05704725 record still lists
NCT05704725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Chorioretinal Vascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Aflibercept is the first listed.
NCT05704725 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05704725 about?
NCT05704725 is a clinical study titled "A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)". The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.
What is the current status of trial NCT05704725?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2023-01-23. Estimated completion is 2023-03-24.
What conditions does trial NCT05704725 study?
This clinical trial studies the following conditions: Chorioretinal Vascular Disease.
What interventions are being tested in trial NCT05704725?
The interventions under investigation include: Aflibercept (DRUG), ABP 938 (DRUG).
Who is sponsoring clinical trial NCT05704725?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05704725 being conducted?
This trial has 4 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05704725's enrollment target sits among peer trials
49 1860th of 2000 higher than 139 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI